ResearcherFirst Affiliated Hospital of Xi'an Jiaotong UniversityNo recent work listed
Suxia Han
Matched on ORCID iD 0000-0003-0842-3908; OpenAlex author ID A5051627278. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 21
2012: 1 paper · 2013: none · 2014: 1 paper · 2015: 2 papers · 2016: none · 2017: none · 2018: none · 2019: 1 paper · 2020: none · 2021: none · 2022: 1 paper
Papers 6
- Repurposing econazole as a pharmacological autophagy inhibitor to treat pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.apsb.2022.01.018↗
- Evaluation of the target genes of arsenic trioxide in pancreatic cancer by bioinformatics analysis. Last author DOI 10.3892/ol.2019.10889↗
- Ginkgolic acid suppresses the development of pancreatic cancer by inhibiting pathways driving lipogenesis. Co-author DOI 10.18632/oncotarget.3663↗
- Serum dickkopf-1 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer. Co-author DOI 10.18632/oncotarget.4529↗
- The role of PAM4 in the management of pancreatic cancer: diagnosis, radioimmunodetection, and radioimmunotherapy. Co-author DOI 10.1155/2014/268479↗
- Immunodiagnostic value of combined detection of autoantibodies to tumor-associated antigens as biomarkers in pancreatic cancer. Co-author DOI 10.1111/j.1365-3083.2011.02657.x↗
Closest collaborators
The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Qing Zhu · 5 shared papers, 2012–2022 · strength 0.34
- Paper Repurposing econazole as a pharmacological autophagy inhibitor to treat pancreatic ductal adenocarcinoma. DOI 10.1016/j.apsb.2022.01.018↗
- Paper Evaluation of the target genes of arsenic trioxide in pancreatic cancer by bioinformatics analysis. DOI 10.3892/ol.2019.10889↗
- Paper The role of PAM4 in the management of pancreatic cancer: diagnosis, radioimmunodetection, and radioimmunotherapy. DOI 10.1155/2014/268479↗
- Ningna Weng · 2 shared papers, 2019–2022 · strength 0.21
- Congya Zhou · 2 shared papers, 2015–2019 · strength 0.14
- Xing Huang · 1 shared paper, 2022 · strength 0.13
- Zhe Zhang · 1 shared paper, 2022 · strength 0.13
- Canhua Huang · 1 shared paper, 2022 · strength 0.13
- Ajay Goel · 1 shared paper, 2022 · strength 0.13
- Guihua Jin · 1 shared paper, 2014 · strength 0.05
- Xiongwei Huo · 1 shared paper, 2015 · strength 0.04
- Jianjun Lei · 1 shared paper, 2015 · strength 0.04
- Liang Han · 1 shared paper, 2015 · strength 0.04
- Ligang Nan · 1 shared paper, 2015 · strength 0.04
- Xin Chen · 1 shared paper, 2015 · strength 0.04
- Zhengdong Jiang · 1 shared paper, 2015 · strength 0.04
- Erxi Wu · 1 shared paper, 2015 · strength 0.04
- Jiguang Ma · 1 shared paper, 2015 · strength 0.04
- Wanxing Duan · 1 shared paper, 2015 · strength 0.04
- Qinhong Xu · 1 shared paper, 2015 · strength 0.04
- Xuqi Li · 1 shared paper, 2015 · strength 0.04
- Zheng Wang · 1 shared paper, 2015 · strength 0.04
- Jinrong Li · 1 shared paper, 2012 · strength 0.03
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.